The spectrum of gut microbiome composition is readily but controversially distilled into a handful of community types. In this issue of Cell Host & Microbe, Lee et al. (2021) find that matching pre-existing community types (and associated molecular biomarkers) to the class of immune biologic therapy in inflammatory bowel disease may double the treatment response.